Ilan Oren
Vorsitzender bei ROIVANT SCIENCES LTD.
Vermögen: 874 850 $ am 30.04.2024
Profil
Ilan Oren is currently the Co-Chief Executive Officer at Dexcel Pharma Technologies Ltd., the Independent Chairman at Roivant Sciences Ltd., the Director at Roivant Sciences, Inc., the Director at Clexio Biosciences Ltd., the Director at Kriya Therapeutics, Inc., and the Director at 8400 - The Health Network.
Previously, he served as the Independent Director at Cynapsus Therapeutics, Inc. from 2013 to 2016, the Director at Sio Gene Therapies, Inc. from 2018 to 2020, and the Non-Executive Director at Sio Gene Therapies, Inc. from 2015 to 2017.
He also held the position of Independent Director at Montes Archimedes Acquisition Corp.
Mr. Oren completed his undergraduate degree at Harvard College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ROIVANT SCIENCES LTD.
0,01% | 24.04.2024 | 80 409 ( 0,01% ) | 874 850 $ | 30.04.2024 |
Aktive Positionen von Ilan Oren
| Unternehmen | Position | Beginn |
|---|---|---|
| ROIVANT SCIENCES LTD. | Vorsitzender | 13.03.2023 |
Dexcel Pharma Technologies Ltd.
 Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Dexcel Pharma Technologies Ltd. develops, manufactures and markets branded and generic pharmaceuticals. Its core products include Deximune, PerioChip, and Omeprazole delayed released tablet. The company was founded by Dan Oren in 1968 and is headquartered in Or Akiva, Israel. | Vorstandsvorsitzender | 10.03.2013 |
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | - |
Kriya Therapeutics, Inc.
 Kriya Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kriya Therapeutics, Inc. designs and develops transformative new treatments for prevalent and severe chronic diseases. The company was founded by Shankar Ramaswamy and Roger Jeffs and is headquartered in Redwood City, CA. | Direktor/Vorstandsmitglied | 01.01.2020 |
Clexio Biosciences Ltd.
 Clexio Biosciences Ltd. Pharmaceuticals: OtherHealth Technology Clexio Biosciences Ltd. develops novel therapies for patients suffering from neurological and psychiatric conditions. The private company is based in Jerusalem, Israel. The Israeli company was founded by Elena Kagan, Elisabeth Kogan, Menashe Levy. Elisabeth Kogan has been the CEO since incorporation. | Direktor/Vorstandsmitglied | 01.01.2018 |
| 8400 - The Health Network | Direktor/Vorstandsmitglied | 01.01.2019 |
Ehemalige bekannte Positionen von Ilan Oren
| Unternehmen | Position | Ende |
|---|---|---|
| SIO GENE THERAPIES INC. | Direktor/Vorstandsmitglied | 24.09.2020 |
| SIO GENE THERAPIES INC. | Direktor/Vorstandsmitglied | 21.12.2017 |
| CYNAPSUS THERAPEUTICS INC | Direktor/Vorstandsmitglied | 21.10.2016 |
| ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Ilan Oren
| Harvard College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ROIVANT SCIENCES LTD. | Health Technology |
| Private Unternehmen | 8 |
|---|---|
Cynapsus Therapeutics, Inc.
 Cynapsus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cynapsus Therapeutics, Inc. operated as a pharmaceutical company, which developed an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. The company was founded by Andrew Williams and David Hill on January 16, 2004 and was headquartered in Toronto, Canada. | Health Technology |
Dexcel Pharma Technologies Ltd.
Dexcel Pharma Technologies Ltd. Pharmaceuticals: MajorHealth Technology Dexcel Pharma Technologies Ltd. develops, manufactures and markets branded and generic pharmaceuticals. Its core products include Deximune, PerioChip, and Omeprazole delayed released tablet. The company was founded by Dan Oren in 1968 and is headquartered in Or Akiva, Israel. | Health Technology |
Sio Gene Therapies, Inc.
 Sio Gene Therapies, Inc. Pharmaceuticals: MajorHealth Technology Sio Gene Therapies, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. The company was founded on October 31, 2014 and is headquartered in New York, NY. | Health Technology |
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
Clexio Biosciences Ltd.
Clexio Biosciences Ltd. Pharmaceuticals: OtherHealth Technology Clexio Biosciences Ltd. develops novel therapies for patients suffering from neurological and psychiatric conditions. The private company is based in Jerusalem, Israel. The Israeli company was founded by Elena Kagan, Elisabeth Kogan, Menashe Levy. Elisabeth Kogan has been the CEO since incorporation. | Health Technology |
Kriya Therapeutics, Inc.
Kriya Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Kriya Therapeutics, Inc. designs and develops transformative new treatments for prevalent and severe chronic diseases. The company was founded by Shankar Ramaswamy and Roger Jeffs and is headquartered in Redwood City, CA. | Commercial Services |
Montes Archimedes Acquisition Corp.
 Montes Archimedes Acquisition Corp. Financial ConglomeratesFinance Montes Archimedes Acquisition Corp operates as a blank check company. It is formed for the business purpose to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded James C. Momtazee and Maria C. Walker on July 6, 2020 and is headquartered in Menlo Park, CA. | Finance |
| 8400 - The Health Network |
